MedTrace Logo

Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes

NCT01697631 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2017-02-24

No results posted yet for this study

Summary

This this trial is conducted in Europe. The aim of this trial is to compare glycaemic control of biphasic insulin aspart 30 (BIAsp 30) alone or combined with insulin aspart(IAsp) in patients previously treated with conventional Biphasic Human Insulin 30/70.

Conditions

Interventions

DRUG

biphasic insulin aspart 30

Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals

DRUG

insulin aspart

Administrated subcutaneously (s.c., under the skin) before lunch

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-22
Primary Completion
2003-04-24
Completion
2003-04-24

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01697631 on ClinicalTrials.gov